Myriad Genetics (MYGN) Non-Current Deferred Tax Liability (2014 - 2023)

Myriad Genetics has disclosed Non-Current Deferred Tax Liability across 10 years of filings, most recently posting $2.7 million for Q3 2023.

• In Q3 2023, Non-Current Deferred Tax Liability fell 74.29% year-over-year to $2.7 million; the TTM figure through Sep 2023 stood at $2.7 million (down 74.29% YoY), while the FY2022 annual figure was $3.5 million, down 97.28% from the prior year.
• Non-Current Deferred Tax Liability slipped to $2.7 million in Q3 2023, from $3.7 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for MYGN reached as high as $174.3 million in Q4 2020 and fell as low as $2.7 million in Q3 2023.
• The 5-year median for Non-Current Deferred Tax Liability is $58.2 million (2021), against an average of $52.7 million.
• Annual changes were most pronounced in 2020 — Non-Current Deferred Tax Liability surged 130.86% — and 2022, when it tumbled 97.28%.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $75.5 million in 2019, then surged by 130.86% to $174.3 million in 2020, then dropped by 26.22% to $128.6 million in 2021, then plunged by 97.28% to $3.5 million in 2022, then decreased by 22.86% to $2.7 million in 2023.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $2.7 million, $3.7 million, and $4.1 million for Q3 2023, Q2 2023, and Q1 2023 respectively.